DRREDDY

During today's trading session, Dr Reddys Laboratories experienced a decline of 0.31%, with the current price at Rs 1,358.50. The stock experienced high trading volume, drawing significant market attention. Dr Reddys Laboratories is included in the NIFTY 50 and NIFTY 100 indices. Financial Overview Dr Reddys Laboratories has demonstrated consistent financial performance over the recent years. The following is a summary of the company’s consolidated financial results. Revenue The company's revenue has shown steady growth over the past few quarters: Mar 2024: Rs 7,113.80 Cr Jun 2024: Rs 7,696.10 Cr Sep 2024: Rs 8,038.20 Cr Dec 2024: Rs 8,381.20 Cr Mar 2025: Rs 8,528.40 Cr Net Profit The net profit figures have also reflected a positive trend: Mar 2024: Rs 1,306.30 Cr Jun 2024: Rs 1,386.50 Cr Sep 2024: Rs 1,335.80 Cr Dec 2024: Rs 1,400.00 Cr Mar 2025: Rs 1,581.20 Cr Earnings Per Share (EPS) The earnings per share have been as follows: Mar 2024: 78.66 Jun 2024: 83.61 Sep 2024: 80.45 Dec 2024: 16.97 Mar 2025: 19.12 Annual Performance Dr Reddys Laboratories' annual financial performance demonstrates a consistent growth trajectory. Annual Revenue The annual revenue figures over the past five years are: 2021: Rs 19,047.50 Cr 2022: Rs 21,545.20 Cr 2023: Rs 24,669.70 Cr 2024: Rs 28,011.10 Cr 2025: Rs 32,643.90 Cr Annual Net Profit The annual net profit is reported as: 2021: Rs 1,903.60 Cr 2022: Rs 2,112.20 Cr 2023: Rs 4,470.30 Cr 2024: Rs 5,563.20 Cr 2025: Rs 5,703.50 Cr Annual EPS The annual earnings per share are: 2021: 117.67 2022: 131.57 2023: 271.47 2024: 335.22 2025: 64.22